Abstract
Bortezomib-based combinations have become the standard frontline approach for the treatment of multiple myeloma in Canada. In non-transplant eligible patients adding bortezomib to the traditional alkylator/steroid backbone has proven to be effective with bortezomib, melphalan and prednisone (VMP) being established as the standard triplet regimen. Building on this, a similar approach using cyclophosphamide and dexamethasone (CyBorD) has been explored. Little data exists for this regimen in the elderly non-transplant setting. Here, the Alberta Myeloma and Dysproteinemia Program presents its experience after adopting CyBorD as the standard regime for transplant ineligible patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
